Introduction：Basic information about PAGOCLONE CAS 133737-32-3, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
PAGOCLONE Basic information
| Product Name: | PAGOCLONE |
| Synonyms: | 2-(7-Chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone;RP 59037;Ip 456;Rp 62955;2-(7-Chloro-1,8-naphthyridin-2-yl)-3-(5-Methyl-2-oxohexyl)isoindolin-1-one;(+)-RP-59037; IP-456; RP-62955; CI-1043;CI-1043;AGOCLONE |
| CAS: | 133737-32-3 |
| MF: | C23H22ClN3O2 |
| MW: | 407.89 |
| EINECS: | 225-799-5 |
| Product Categories: | |
| Mol File: | 133737-32-3.mol |
|
PAGOCLONE Chemical Properties
| Boiling point | 582.1±50.0 °C(Predicted) |
| density | 1.273±0.06 g/cm3(Predicted) |
| form | Solid |
| pka | 1.62±0.30(Predicted) |
| color | White to off-white |
| InChI | InChI=1S/C23H22ClN3O2/c1-14(2)7-10-16(28)13-19-17-5-3-4-6-18(17)23(29)27(19)21-12-9-15-8-11-20(24)25-22(15)26-21/h3-6,8-9,11-12,14,19H,7,10,13H2,1-2H3 |
| InChIKey | HIUPRQPBWVEQJJ-UHFFFAOYSA-N |
| SMILES | C1(=O)C2=C(C=CC=C2)C(CC(=O)CCC(C)C)N1C1=CC=C2C(=N1)N=C(Cl)C=C2 |
Safety Information
PAGOCLONE Usage And Synthesis
| Description | Pagoclone is a drug that belongs to the class of cyclopyrrolones. It binds to the benzodiazepine binding site on GABAA receptors and acts as a negative allosteric modulator, thereby enhancing the inhibitory effects of GABA and reducing neuronal excitability. |
| Uses | Anti-anxiety agent. |
| Application | Pagoclone has been shown to have anti-inflammatory properties in an animal model of inflammatory bowel disease and may be useful for the treatment of this condition. |
| Brand name | Bextra (Interneuron). |
| in vivo | Pagoclone (3 mg/kg, p.o.) has significant anxiolytic-like activity, but at all three doses tested (0.3, 1 and 3 mg/kg p.o.) it produces a significant reduction in the total distance travelled. Pagoclone (3 mg/kg, p.o.) produces a dose-dependent increase in time spent on the open arms compared to control. Pagoclone (1, 3 or 10 mg/kg) lowers the cumulative chain-pulling response in the response sensitivity test. Plasma pagoclone concentrations are dose-dependent but not linear, with plasma concentrations of pagoclone being 0.4±0.1, 1.1±0.2 and 2.2±0.2 ng/mL, respectively. Pagoclone (0.3, 1 or 3 mg/kg) reduces locomotor activity in rats in a dose dependent manner[1]. |
PAGOCLONE Preparation Products And Raw materials
